So Far, So Good: Vyne Reports Positive Phase 1a Data for Novel BD2-Selective BET Inhibitor
VYNE Therapeutics’ VYN202, which is under development for treating chronic inflammatory and immune-mediated conditions, performed well in the single ascending dose part of an ongoing Phase 1a trial, the Company reports. VYN202 was generally well tolerated with no drug-related adverse events, and pharmacokinetic results demonstrated dose-dependent exposure of VYN202 in blood. VYN202 is an oral […]